B
IMCR icon

Braidwell’s Immunocore IMCR Stock Holding History

Braidwell’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-797,268
Closed -$27M – 84
2024
Q2 		$27M Buy
+797,268
New +$40.7M 0.85% 42
2024
Q1 		– Sell
-611,365
Closed -$41.8M – 76
2023
Q4 		$41.8M Sell
611,365
-295,608
-33% -$15.4M 1.53% 24
2023
Q3 		$47.1M Buy
906,973
+438,946
+94% +$26M 1.49% 21
2023
Q2 		$28.1M Buy
468,027
+41,917
+10% +$2.39M 0.92% 40
2023
Q1 		$21.1M Buy
+426,110
New +$24M 0.69% 50

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Braidwell's IMCR Position: Q3 2024 in Review

Braidwell sold out of Immunocore (IMCR) in Q3 2024, closing a stake of 797,268 shares — an estimated $27M sold.

Braidwell first reported a position in IMCR in Q1 2023 and held it in 5 quarters. The position peaked at $47.1M in Q3 2023. 130 funds tracked by Wall St. Rank hold IMCR as of Q3 2024.

  • Braidwell reported no remaining Immunocore position as of Q3 2024 after selling out during the quarter.
  • Braidwell sold 797,268 Immunocore shares in Q3 2024, an estimated $27M.
  • Braidwell first reported a position in Immunocore in Q1 2023 and held it in 5 quarters.
  • Braidwell's Immunocore position peaked at $47.1M in Q3 2023.
  • 130 funds tracked by Wall St. Rank held Immunocore as of Q3 2024.

Based on Braidwell's 13F filing for Q3 2024, filed 14 Nov 2024.